Loncastuximab Tesirine Clinical Trials
9 recruitingDrug
Phase 27Phase 12
Showing 1–9 of 9 trials
Recruiting
Phase 1
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
ADC Therapeutics S.A.200 enrolled42 locationsNCT04970901
Recruiting
Phase 2
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
RelapseLarge B-cell Lymphoma
University of Miami26 enrolled1 locationNCT06919939
Recruiting
Phase 2
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
LymphomaLarge B-cell Lymphoma
M.D. Anderson Cancer Center30 enrolled1 locationNCT05464719
Recruiting
Phase 2
Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)
Relapsed or Refractory Large B-cell Lymphoma
University of Utah29 enrolled1 locationNCT06788964
Recruiting
Phase 2
Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma
High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsDouble-Expressor Lymphoma+1 more
Joseph Tuscano24 enrolled2 locationsNCT05600686
Recruiting
Phase 2
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
Recurrent Follicular LymphomaRefractory Follicular LymphomaRecurrent B-Cell Non-Hodgkin Lymphoma+8 more
University of Washington40 enrolled1 locationNCT05453396
Recruiting
Phase 2
Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Recurrent Transformed Chronic Lymphocytic LeukemiaRefractory Transformed Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell Lymphoma+9 more
City of Hope Medical Center36 enrolled1 locationNCT05672251
Recruiting
Phase 1
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
ADC Therapeutics S.A.56 enrolled14 locationsNCT05660395
Recruiting
Phase 2
Loncastuximab Tesirine in WM
Waldenstrom Macroglobulinemia
Shayna Sarosiek, MD36 enrolled4 locationsNCT05190705